Neuphoria Therapeutics (NEUP) Operating Expenses (2023 - 2026)

Neuphoria Therapeutics (NEUP) has 4 years of Operating Expenses data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Operating Expenses fell 59.92% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.7 million (up 1.9% YoY) and the FY2025 annual result came in at $16.8 million, down 6.23% from the prior year.
• Operating Expenses retreated to $1.2 million in Q1 2026 per NEUP's latest filing, from $4.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $5.8 million in Q2 2025 and bottomed at $1.2 million in Q1 2026.
• The 4-year median for Operating Expenses is $4.4 million (2024), against an average of $4.1 million.
• The widest annual swing landed in 2025, when Operating Expenses jumped 58.44%; it then tumbled 59.92% in 2026.
• Tracing NEUP's Operating Expenses over 4 years: stood at $4.6 million in 2023, then slipped by 4.1% to $4.4 million in 2024, then slipped by 6.99% to $4.1 million in 2025, then sank by 70.16% to $1.2 million in 2026.
• Per Business Quant, the three latest NEUP Operating Expenses figures stand at $1.2 million (Q1 2026), $4.1 million (Q4 2025), and $5.7 million (Q3 2025).

Peer Comparison